Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Clin Cancer Res. 2022 Sep 1;28(17):3658-3668. doi: 10.1158/1078-0432.CCR-22-0588.
Clin Cancer Res. 2022.
PMID: 35727601
Free PMC article.
Clinical Trial.
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA).
Jiménez-Cortegana C, et al. Among authors: galvez carvajal l.
J Immunother Cancer. 2021 Jun;9(6):e002323. doi: 10.1136/jitc-2020-002323.
J Immunother Cancer. 2021.
PMID: 34158317
Free PMC article.
Item in Clipboard
Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.
Gutiérrez Calderón V, Cantero González A, Gálvez Carvajal L, Aguilar Lizarralde Y, Rueda Domínguez A.
Gutiérrez Calderón V, et al. Among authors: galvez carvajal l.
Ther Adv Med Oncol. 2021 Feb 23;13:1758835920984061. doi: 10.1177/1758835920984061. eCollection 2021.
Ther Adv Med Oncol. 2021.
PMID: 33747147
Free PMC article.
Review.
Item in Clipboard
Targeted treatment approaches in refractory germ cell tumors.
Galvez-Carvajal L, Sanchez-Muñoz A, Ribelles N, Saez M, Baena J, Ruiz S, Ithurbisquy C, Alba E.
Galvez-Carvajal L, et al.
Crit Rev Oncol Hematol. 2019 Nov;143:130-138. doi: 10.1016/j.critrevonc.2019.09.005. Epub 2019 Sep 25.
Crit Rev Oncol Hematol. 2019.
PMID: 31634730
Free article.
Review.
Item in Clipboard
Liquid Biopsy as a Tool for the Characterisation and Early Detection of the Field Cancerization Effect in Patients with Oral Cavity Carcinoma.
Pérez-Ruiz E, Gutiérrez V, Muñoz M, Oliver J, Sánchez M, Gálvez-Carvajal L, Rueda-Domínguez A, Barragán I.
Pérez-Ruiz E, et al. Among authors: galvez carvajal l.
Biomedicines. 2021 Oct 15;9(10):1478. doi: 10.3390/biomedicines9101478.
Biomedicines. 2021.
PMID: 34680596
Free PMC article.
Review.
Item in Clipboard
Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.
Galvez-Carvajal L, Quero C, Casanova M, Díaz C, Chícharo JR, Espeso M, Medina Á, Ramos I, Alba E, Rueda A.
Galvez-Carvajal L, et al.
Int J Hematol. 2022 Jan;115(1):54-60. doi: 10.1007/s12185-021-03223-6. Epub 2021 Sep 21.
Int J Hematol. 2022.
PMID: 34546542
Item in Clipboard
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.
Ribelles N, Pascual J, Galvez-Carvajal L, Ruiz-Medina S, Garcia-Corbacho J, Benitez JC, Dominguez-Recio ME, Torres E, Oliva L, Zalabardo M, Rueda A, Alba E.
Ribelles N, et al. Among authors: galvez carvajal l.
JCO Glob Oncol. 2024 Mar;10:e2300363. doi: 10.1200/GO.23.00363.
JCO Glob Oncol. 2024.
PMID: 38513186
Free PMC article.
Item in Clipboard
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio-Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L.
Hontecillas-Prieto L, et al. Among authors: galvez carvajal l.
Front Immunol. 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. eCollection 2024.
Front Immunol. 2024.
PMID: 38469299
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite